Aclaris Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-22$4.53 RISE2026-02-27$2.87 PEAK2026-05-13$5.09 111d | -36.6% 36d | Missed | Missed | — | — | +77.4% 75d | Missed |
DROP2025-12-11$3.36 RISE2026-01-16$2.62 PEAK2026-01-22$4.53 42d | -22.0% 36d | Missed | Missed | — | — | +72.9% 6d | Missed |
DROP2025-09-09$2.13 RISE2025-10-14$1.81 PEAK2025-12-11$3.36 93d | -15.0% 35d | Missed | Missed | — | — | +85.6% 58d | Missed |
DROP2024-11-29$4.07 RISE2025-04-10$1.08 PEAK2025-06-25$1.63 208d | -73.5% 132d | Missed | Missed | — | — | +50.9% 76d | Missed |
DROP2024-07-23$1.40 RISE2024-09-25$1.12 PEAK2024-11-19$4.59 119d | -20.0% 64d | Missed | Missed | — | — | +309.8% 55d | Missed |
DROP2024-07-23$1.40 RISE2024-08-12$1.14 PEAK2024-11-05$2.22 105d | -18.6% 20d | Missed | Missed | — | — | +94.7% 85d | Missed |
DROP2024-03-06$1.44 RISE2024-06-07$1.01 PEAK2024-07-23$1.40 139d | -29.9% 93d | Missed | Missed | — | — | +38.6% 46d | Missed |
DROP2024-03-06$1.44 RISE2024-06-04$1.01 PEAK2024-07-23$1.40 139d | -29.9% 90d | Missed | Missed | — | — | +38.6% 49d | Missed |
DROP2024-03-06$1.44 RISE2024-05-29$1.01 PEAK2024-07-23$1.40 139d | -29.9% 84d | Missed | Missed | — | — | +38.6% 55d | Missed |
DROP2023-11-10$4.76 RISE2024-03-22$1.15 PEAK2024-05-03$1.36 175d | -75.8% 133d | Missed | Missed | — | — | +18.3% 42d | Missed |
DROP2023-11-08$5.45 RISE2024-03-19$1.15 PEAK2024-05-03$1.36 177d | -78.9% 132d | Missed | Missed | — | — | +18.3% 45d | Missed |
DROP2023-11-06$5.48 RISE2024-03-18$1.15 PEAK2024-05-03$1.36 179d | -79.0% 133d | Missed | Missed | — | — | +18.3% 46d | Missed |
DROP2023-11-06$5.48 RISE2024-03-14$1.15 PEAK2024-05-03$1.36 179d | -79.0% 129d | Missed | Missed | — | — | +18.3% 50d | Missed |
DROP2023-09-14$8.00 RISE2024-01-12$0.92 PEAK2024-03-06$1.44 174d | -88.5% 120d | Missed | Missed | — | — | +55.8% 54d | Missed |
DROP2023-07-14$10.95 RISE2023-11-13$0.65 PEAK2024-01-09$1.28 179d | -94.1% 122d | Missed | Missed | — | — | +98.4% 57d | Missed |
1–15 / 29 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Aclaris Therapeutics, Inc. (ACRS) Bank of America Global Healthcare Conference 2026 May 14, 2026 12:35 PM EDTCompany ParticipantsHugh M.
Presenter SpeechHugh M. Davis study in atopic derm, where the data showed over 90% of subjects had an es75 response and an IgA-01, 88% response. So we've taken this forward into a Phase IIb or a...
WAYNE, Pa., May 08, 2026 -- Aclaris Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced...
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 2 million compared to USD 1.46 million a...
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.
WAYNE, Pa. — WAYNE, Pa. — Aclaris Therapeutics Inc. on Thursday reported a loss of $19.8 million in its first quarter. On a per-share basis, the Wayne, Pennsylvania-based company said it had...
Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris’ Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique...
Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Aclaris...
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and raises the price target from $8 to $10.
Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ATI-052 and outlining plans to advance oral candidate ATI-2138 into a phase IIb program in li
2026-04-28. The following slide deck was published by Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates April 28, 2026 8:30 AM EDTCompany...
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the Aclaris Clinical Program Update Call. [Operator Instructions] Please be advised that today's conference
Aclaris Therapeutics Inc: Aclaris Therapeutics announces positive full top line first-in-human results from Phase 1a healthy volunteer clinical trial of ATI-052, a novel potential first-in-class...
Clinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus April 28, 2026 ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACRS | +3.17% | +49.18% | +51.16% | +211.64% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.21% | +54.90% | +54.61% | +198.96% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.01M | $7.53M | 0.00% | Added+33.3% | 2026-03-31 |
| DEShaw | quant | 900.8K | $3.38M | 0.00% | Trimmed-57.0% | 2026-03-31 |
| RenTech | quant | 502.6K | $1.88M | 0.00% | Trimmed-55.3% | 2026-03-31 |
| TwoSigma | quant | 395.6K | $1.48M | 0.00% | Trimmed-31.1% | 2026-03-31 |
| Wellington | fundamental | 257.2K | $964.34K | 0.00% | Trimmed-2.7% | 2026-03-31 |
| FidelityFMR | fundamental | 176.4K | $661.32K | 0.00% | Added+285.0% | 2026-03-31 |
| TRowePrice | fundamental | 156.7K | $588 | 0.00% | Added+11.8% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | Hall Jesse Wayne | Chief Medical Officer | M Option exercise(deriv) | 36,375 | — | +$0 |
| 2026-05-05 | Hall Jesse Wayne | Chief Medical Officer | F Tax withholding | 9,330 | $4.41 | −$41.1K |
| 2026-05-05 | Hall Jesse Wayne | Chief Medical Officer | M Option exercise | 36,375 | — | — |
| 2026-04-27 | Leonard Braden Michael | 10% Owner | S Open-market sale | 300,000 | $4.53 | −$1.36M |
| 2026-03-03 | Balthaser Kevin | Chief Financial Officer | M Option exercise(deriv) | 2,375 | — | +$0 |
| 2026-03-03 | Balthaser Kevin | Chief Financial Officer | F Tax withholding | 677 | $2.87 | −$1.9K |
| 2026-03-03 | Balthaser Kevin | Chief Financial Officer | M Option exercise | 2,375 | — | — |
| 2026-02-06 | Balthaser Kevin | Chief Financial Officer | A Grant / award(deriv) | 346,800 | — | +$0 |
| 2026-02-06 | Balthaser Kevin | Chief Financial Officer | A Grant / award(deriv) | 99,100 | — | +$0 |
| 2026-02-06 | Loerop James | Chief Business Officer | A Grant / award(deriv) | 341,900 | — | +$0 |
| 2026-02-06 | Loerop James | Chief Business Officer | A Grant / award(deriv) | 97,700 | — | +$0 |
| 2026-02-06 | Hall Jesse Wayne | Chief Medical Officer | A Grant / award(deriv) | 343,300 | — | +$0 |
| 2026-02-06 | Hall Jesse Wayne | Chief Medical Officer | A Grant / award(deriv) | 98,100 | — | +$0 |
| 2026-02-06 | Kolbeck Roland Wilhelm | Chief Scientific Officer | A Grant / award(deriv) | 334,900 | — | +$0 |
| 2026-02-06 | Kolbeck Roland Wilhelm | Chief Scientific Officer | A Grant / award(deriv) | 95,700 | — | +$0 |
| 2026-02-06 | Davis Hugh M. | President and COO | A Grant / award(deriv) | 336,300 | — | +$0 |
| 2026-02-06 | Davis Hugh M. | President and COO | A Grant / award(deriv) | 96,100 | — | +$0 |
| 2026-02-06 | Walker Neal | CEO | A Grant / award(deriv) | 961,700 | — | +$0 |
| 2026-02-06 | Walker Neal | CEO | A Grant / award(deriv) | 274,800 | — | +$0 |
| 2026-02-05 | Balthaser Kevin | Chief Financial Officer | M Option exercise(deriv) | 22,025 | — | +$0 |
| 2026-02-05 | Balthaser Kevin | Chief Financial Officer | F Tax withholding | 6,449 | $3.47 | −$22.4K |
| 2026-02-05 | Balthaser Kevin | Chief Financial Officer | M Option exercise | 22,025 | — | — |
| 2026-02-05 | Davis Hugh M. | President and COO | M Option exercise(deriv) | 18,675 | — | +$0 |
| 2026-02-05 | Davis Hugh M. | President and COO | M Option exercise | 18,675 | — | — |
| 2026-02-05 | Walker Neal | CEO | M Option exercise(deriv) | 63,475 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.16 | — | — |
| 2026-05-07 | -0.16 | -0.15 | +4.93% |
| 2026-02-26 | -0.14 | -0.16 | -17.07% |
| 2025-11-06 | -0.14 | -0.12 | +14.29% |
| 2025-08-07 | -0.13 | -0.13 | -1.30% |
| 2025-05-08 | -0.12 | -0.12 | — |
| 2025-02-27 | -0.37 | -1.01 | -169.33% |
| 2024-11-06 | -0.01 | -0.11 | -1275.00% |
| 2024-08-07 | -0.20 | -0.15 | +24.37% |
| 2024-05-07 | -0.32 | -0.24 | +24.53% |
| 2024-02-27 | -0.39 | -0.02 | +94.85% |
| 2023-11-06 | -0.49 | -0.41 | +16.04% |
| 2023-08-07 | -0.45 | -0.42 | +7.35% |
| 2023-05-08 | -0.44 | -0.42 | +4.91% |
| 2023-02-23 | -0.44 | -0.41 | +6.82% |
| 2022-11-08 | -0.40 | -0.30 | +25.93% |